@article{e81a89b903bc458a844db69ff2ecfc59,
title = "Age-Specific Barriers and Facilitators to Research Participation Amongst African Americans in Observational Studies of Memory and Aging",
abstract = "Background: Black/African Americans experience a high burden of Alzheimer disease and related dementias yet are critically underrepresented in corresponding research. Understanding barriers and facilitators to research participation among younger and older African Americans is necessary to inform age-specific strategies to promote equity in studies of early- and late-onset neurodegenerative diseases. Study Design: Survey respondents (n = 240) rated barriers and facilitators of research participation. Age-specific differences were evaluated using nonparametric Kruskal–Wallis tests across respondents aged 18–44 years (n = 76), 45–64 years (n = 83), and ≥ 65 years (n = 81). Strategies to mitigate barriers and promote facilitators were further explored via community-based focus groups. Pooled frequency of common themes discussed in focus groups were evaluated and compared across different ages including ≥ 45 years, ≥ 65 years, and mixed ages ≥ 45 years. Results: Younger respondents (aged 18–44 and 45–64 years) expressed a greater need for flexibility in when, where, and how research testing takes place versus adults ≥ 65 years. Focus groups emphasized long-lasting consequences of systemic racism and the need to build and foster trust to resolve barriers and promote research engagement amongst African Americans. Discussion: Age-specific strategies are needed to increase engagement, address recruitment disparities, and promote retention of African American participants in memory and aging studies across the lifespan.",
keywords = "African Americans, Alzheimer disease, Alzheimer disease-related dementia, Barriers, Facilitators, Research participation",
author = "Nissim, {Nicole R.} and Fudge, {Michelle R.} and Christian Lachner and Babulal, {Ganesh M.} and Allyse, {Megan A.} and Graff-Radford, {Neill R.} and Lucas, {John A.} and Gregory Day",
note = "Funding Information: JA Lucas is supported by NIH (P30AG62677, U01NS100620-6, U19AG074879-1). He serves as site-PI of an ACTC subaward to increase diverse representation of participants in the AHEAD Clinical Trial. Funding Information: GS Day is supported by NIH (K23AG064029, U01AG057195, U19AG032438), the Alzheimer{\textquoteright}s Association, and Chan Zuckerberg Initiative. He serves as a consultant for Parabon Nanolabs Inc, as a Topic Editor (Dementia) for DynaMed (EBSCO), and as the Clinical Director of the Anti-NMDA Receptor Encephalitis Foundation (Inc, Canada; uncompensated). He is the co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from Horizon Pharmaceuticals. He has developed educational materials for PeerView Media, Inc, and Continuing Education Inc. He owns stock in ANI pharmaceuticals. Dr. Day{\textquoteright}s institution has received support from Eli Lilly for Dr. Day{\textquoteright}s development and participation in an educational event promoting early diagnosis of symptomatic Alzheimer disease. Funding Information: GM Babulal{\textquoteright}s research is supported by NIH/NIA (R01AG068183, R01AG067428, R01AG074302, R01AG074302), BrightFocus Foundation (A2021142S), and Alzheimer{\textquoteright}s Association. Funding Information: This work was supported by the Alzheimer{\textquoteright}s Association LEADS Diversity Recruitment Funding Program [21–824473] and NIH/NIA [K23 AG064029]. Publisher Copyright: {\textcopyright} 2023, W. Montague Cobb-NMA Health Institute.",
year = "2023",
doi = "10.1007/s40615-023-01741-z",
language = "English",
journal = "Journal of Racial and Ethnic Health Disparities",
issn = "2197-3792",
}